A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India

Summary

The purpose of this study was to evaluate the humoral immunogenicity and safety of 2 doses of GSK Biologicals' Herpes Zoster subunit vaccine (HZ/su) administered for the prevention of Herpes Zoster (HZ) in adults aged 50 years of age (YOA) or older from India.

Timeline

Start

2022-02-02

Primary completion

2022-10-11

Completion

2022-12-12

Publications

• Background Naficy A, Chugh Y, Tariq M, Hawksworth H, Sankhe LR, Mwakingwe-Omari A. Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial. Vaccine. 2025 Mar 19;50:126819. doi: 10.1016/j.vaccine.2025.126819. Epub 2025 Feb 10.
• de Oliveira Gomes J, Gagliardi AM, Andriolo BN, Torloni MR, Andriolo RB, Puga MEDS, Canteiro Cruz E. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2023 Oct 2;10(10):CD008858. doi: 10.1002/14651858.CD008858.pub5.

Drugs

Indications